Related Experiment Video
Updated: Jul 14, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Pulmonary arterial hypertension: an overview
1Division of Pulmonary, Sleep and Critical Care Medicine, Rhode Island Hospital, Brown Medical School, Providence, Rhode Island 02903, USA. james_klinger@brown.edu
Abstract:
Pulmonary arterial hypertension (PAH) was first described over 100 years ago, but a thorough understanding of its patho-genesis and a successful approach to curing the disease remain elusive. Increased research activity has greatly enhanced our understanding of the disease and led to new therapies that retard disease progression and improve patient function and survival. The disease is rare, but effects people of all ages and is associated with several seemingly unconnected diseases. It is not clear whether all forms of PAH represent the same disease or the same pathologic endpoint of different pulmonary vascular disease processes. Recent attempts to classify different forms of pulmonary hyper-tension by the diseases with which they are associated has helped researchers organize data collected from patient registries and clinical trials. This overview discusses the history, epidemiology, and genetic basis of PAH, new recommendations for disease classification, and prognostic variables shown to adversely affect survival.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pulmonary Embolism I: Introduction

